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We have developed a simple, direct and time-resolved method to monitor ligand-induced changes in 
agonist affinity of the membrane-bound acetylcholine receptor. The assay is based on the quenching of 
fluorescence of NBD-5-acylcholine observed upon binding of this cholinergic agonist to the receptor. 
Under conditions of partial saturation with the fluorescent agonist, agonists and local anesthetics but not 
antagonists can induce an increase in affinity of the receptor for NBD-5-acylcholine. The effect is not 
observed with receptor fully saturated with the fluorescent agonist. The half-life of the observed change 
in affinity is independent of the nature of the agonist or local anesthetic applied (tl,z -60 s at 22°C). We 
conclude that the same state transition of the receptor can be induced by two groups of cholinergic ligands 
that are assumed to be non-competitive with each other and to have distinctly different modes of action. 
The time course of the transition is reminiscent of the slow process of desensitization bserved in vivo. 
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1. INTRODUCTION 
A convenient approach to analysis of the elec- 
trophysiological data on muscle excitation in more 
molecular terms is the assumption of 3 states of the 
acetylcholine receptor integral cation channel [ 1,2]; 
an active (ion conducting) and two inactive (the 
resting and the desensitized) states. Acetylcholine 
and its agonists are assumed to convert the resting 
into the active state and to induce conversion of 
the active to the desensitized state. Antagonists 
which bind mutually exclusively with agonists to 
the receptor are assumed to interact only with the 
resting state. Local anesthetics which bind to 
separate sites [3] but, in addition, can interfere 
with the binding of other ligands to the receptor 
are also assumed to cause state transitions of the 
agonist activated channel [4]. 
To probe further into the molecular basis of the 
primary events of muscle excitation, biochemical 
correlates to the established electrophysiological 
phenomena re required. We have approached this 
problem by studying with rapid mixing techniques 
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the interaction of affinity-purified acetylcholine 
receptor with the full agonist NBD-Sacylcholine 
[5-71. Expanding this work to the receptor in its 
natural membrane environment, we demonstrate 
here ligand-specific state transitions of the acetyl- 
choline receptor. We show that agonists and local 
anesthetics but not antagonists can induce a state 
transition of the receptor that by its time course 
correlates with the slow process of desensitization 
observed with intact muscle endplates and recon- 
stituted systems. 
2. EXPERIMENTAL 
Acetylcholine receptor-rich membrane vesicles 
from Torpedo marmorata were prepared as in 
[8], with the concentration of NBD-5acylcholine 
binding sites obtained by equilibrium binding 
studies [8,9]. Fluorescence kinetic and equilibrium 
binding studies were performed as in [6,7]. 
The membrane fragments (approx. lo-‘M in 
a-toxin binding sites) were stored at 4°C in 10 mM 
sodium phosphate, 10mM NaNs, 5 mM EDTA 
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(pH7.4) and used within 6 days of their prepara- 
tion. For the actual experiments, the membrane 
fragments were diluted (lOO-fold or more) into 
standard buffer (100 mM NaCl, 4 mM CaC12 2 mM 
MgC12, 10mM Pipes; pH 6.8) and preincubated 
with Tetram for 30min at 4°C. Subsequently 
NBD-5acylcholine in standard buffer was added 
in a small volume (<OS% of the total) and the 
mixture was further incubated at room tempera- 
ture for at least 15 min. These solutions were then 
employed in the equilibrium binding and stopped- 
flow experiments detailed in the figure legends. 
The concentration of NBD-5acylcholine binding 
sites and the degree of receptor saturation were 
calculated assuming model la of authors in [7] and 
a KD value of 17 nM for both classes of sites [9]. 
3. RESULTS AND DISCUSSION 
In the experiments described below, the concen- 
tration of receptor and NBD-5acylcholine was 
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kept constant throughout. Since receptor was pre- 
equilibrated with fluorescent ligand, the initial 
level of fluorescence (origin in the plots) related to 
the relative amounts of bound and free ligand in 
the reaction mixture. Since binding of the fluores- 
cent ligand to the receptor is accompanied by fluo- 
rescence quenching, the increase in fluorescence in 
the course of the experiments correlated with a de- 
crease in the concentration of bound NBD-5-acyl- 
choline and vice versa, 
Fig.1 shows the changes in fluorescence vs time 
observed after rapid mixing of a preequilibrated 
mixture of membrane vesicles and NBD-5-acylcho- 
line with either d-tubocurarine (left) or acetyl- 
choline (right). Addition of d-tubocurarine caused 
an increase in fluorescence, the equilibrium value 
(determined at 100s) of which agreed with the 
amount of NBD-5-acylcholine competed from the 
receptor by the antagonist [9]. Addition of acetyl- 
choline caused more complicated effects: At high 
concentrations of acetylcholine (traces 3-5), i.e., 
when most or all of the receptor is occupied by 
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Fig.1. Kinetics of competition of non-fluorescent cholinergic ligands with preformed complexes of AChR-rich mem- 
brane fragments from Torpedo marmorata and NBD-S-acylcholine. (Left) Membrane fragments, approx. 0.08pM in 
NBD-S-acyicholine binding sites, were preequilibrated with 0.045/M fluorescent ligand resulting in approx. 40% 
saturation of the binding sites [9]. Equal volumes of this reaction mixture and of d-tubocurarine, both in standard 
buffer (1OOmM NaCl, 2 mM MgClz, 4 mM CaC12 1OmM Pipes; pH 6.8) were rapidly mixed in a Durrum DlOO stopped- 
flow spectrofluorimeter and the fluorescence was recorded as a function of time. The concentrations of d-tubocurarine 
after mixing were (from below) 0.01, 0.05 and O.SrM, respectively. The arrow at the right indicates the final level of 
fluorescence achieved with the highest concentration. (Right) Under otherwise identical experimental conditions 
acetylcholine instead of tubocurarine was employed in the stopped-flow experiments. The concentrations of acetyl- 
choline after mixing were (1) O.O15pM, (2) O.O3pM, (3) 0.3#M, (4) 3aM and (5) 30pM. Rate constant of the fluores- 
cence decay observed in traces 1 and 2 and determined as in [27]: kapp = 0.0175 s-l. (The traces shown are each the 
average of 4 experiments performed successively under otherwise identical conditions.) 
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acetylcholine at equilibrium, the pattern resembled tion preceding the increase in affinity for the fluor- 
that observed with d-tubocurarine. At lower con- escent ligand, the rate of dissociation of bound 
centration of acetylcholine (traces 1,2), however, fluorescent ligand was faster than the rate of the 
an initial increase in fluorescence was followed by state transition. Thus, we do not know at present 
an additional decrease in fluorescence not ob- whether a preexisting equilibrium between two or 
served with d-tubocurarine. Given the appropriate more affinity states of the non-liganded receptor is 
conditions (trace 2), the final level of fluorescence shifted in the presence of agonist in the direction of 
was even lower than that prior to mixing. We in- the high-affinity state(s) [16,17] or whether particu- 
terpret this observation as the result of two parallel lar forms of the liganded receptor are responsible 
processes, the usual ligand competition (as in the for the observed high affinity of binding for 
case of d-tubocurarine) and a state transition in- agonists [2,7]. It is clear, however, that the size of 
duced by the binding of acetylcholine. Since this the effect correlates with the probability of forma- 
state transition is observed as a decrease in fluores- tion of mixed diliganded complexes of the receptor, 
cence, it is accompanied by an increase in fluor- i.e., competing agonist :receptor: NBD-5-acylcho- 
escent ligand bound. line. 
One simple explanation for this effect is to as- 
sume that binding of acetylcholine to one of the 
two sites [2,6] of previously unoccupied receptor 
increases the affinity for agonists of the second of 
the two sites. This then leads to preferential (and 
additional) binding of NBD-5-acylcholine to these 
sites thereby causing the observed decrease in total 
fluorescence. The proposed explanation is equiva- 
lent with the assumptions of positively cooperative 
interactions between the two agonist sites at the 
receptor [4,8] and additivity of binding of agonists. 
It also rationalizes the fact that the effect is ob- 
served only with partially saturated receptor. 
The concentration dependence of the observed 
changes in total fluorescence of the reaction mixture 
was also studied under equilibrium conditions. For 
this purpose, aliquots of competing ligand were in- 
jected into a cuvette containing membrane vesicles 
and a non-saturating concentration of NBD-5- 
Similar experiments were performed with a var- 
iety of other non-fluorescent agonists and antago- 
nists. Consistent with the observations described 
above, only agonists and the metaphilic antagonist 
hexamethonium [lo, 1 l] caused an increase in the 
affinity of binding for NBDJ-acylcholine after the 
initial phase of competition. From the range of 
agonist concentrations required to induce compar- 
able effects as shown in fig. 1, a strong correlation 
with the apparent dissociation constants of these 
ligands was observed. For instance, carbamoylcho- 
line showed its maximal effect at 0.4,uM and 
acetylcholine at 0.024pM. In all experiments, i.e., 
independent of the specific agonist applied, the 
half-life of the slow isomerisation step was approx. 
60 s at 22°C. This half-life is similar to that of the 
slow process of desensitization observed in electro- 
physiological experiments with frog endplates 
[12,13], in ion-flux experiments with Torpedo 
membrane vesicles [14] and in patch-clamp studies 
with reconstituted Torpedo receptor [15]. 
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Fig.2. Competition at equilibrium of non-fluorescent 
cholinergic ligands with preformed complexes of mem- 
brane-bound acetylcholine receptor and NBDd-acyl- 
choline. Membrane fragments, approx. O.OSrM in 
NBD-5-acylcholine binding sites, were preequilibrated 
with 0.037rM NBD-5-acylcholine resulting in approx. 
49% saturation of the receptor’s ligand binding sites [9]. 
Into 2ml of this solution in a fluorescence cuvette, 
gallamine (0) or carbamoylcholine (0) was added in 
steps (8~1 per step) employing a Hamilton Microlab P 
titrator [6]. Following each application, the fluorescence 
(Aex = 480 nm, 1 nm bandwidth, emission recorded 
through a Dietrich 520nm cut-on filter) was recorded 
As is apparent from the initial phase of competi- for 500s. 
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acylcholine. After equilibrium was achieved, the 
fluorescence was recorded followed by the addi- 
tion of the next aliquot of competing ligand. As ex- 
emplified in fig.2 for the agonist carbamoylcholine 
and the ~tagonist gallamine, only agonists howed 
a biphasic pattern under these conditions. At low 
concentration of agonist, the increase in affinity of 
binding for NBD-5-acylcholine outweighed the 
competing effect and a net decrease in fluorescence 
(increase in fluorescent ligand bound) was ob- 
served. With increasing concentration of agonist 
the competing effect became increasingly domi- 
nant resulting in complete recovery of fluorecence 
(complete removal of the bound fluorescent 
ligand) at sufficiently high agonist concentration. 
In contrast, antagonists did not cause any decrease 
in total fluorescence and, thus, did not induce this 
state transition. (A close inspection of the experi- 
ment with d-tubocurarine (fig. 1, lowest trace) indi- 
cates, however, that this ligand may induce the 
observed state transition to a very limited extent. 
This may relate to a more complicated binding pat- 
tern [18] and direct channel blocking properties 
[19] of this ligand.) 
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Fig.3. Kinetics of interaction of local anesthetics with 
preformed complexes of AChR-rich membrane frag- 
ments and NBD-5acylcholine. The concentrations of
receptor and NBD-5-acylcholine were identical to those 
indicated in fig. 1. Equal volumes of this reaction mix- 
ture and of either procaine (upper trace) or dibucaine 
(lower trace) were rapidly mixed and the fluorescence 
was recorded as a function of time. Each trace shown 
represents he average of 4 experiments performed suc- 
cessively under otherwise identical conditions. The con- 
centrations after mixing were 5OOpm for procaine and 
lO/tM for dibucaine. Rate constants of the fluorescence 
decay obtained as in [27]: procaine, k,,, = O.OlOs-‘; 
dibucaine, kapp = 0.015 s-l. 
The observed state transition is also induced by 
local anesthetics as shown in fig.3. The simple 
effect caused by the rather lipophilic local anesthe- 
tic dibucaine (fig.3, lower trace) appeared consis- 
tent with its action as a mainly non-competitive 
blocking agent of the receptor [20]. The kinetic 
pattern almost exclusively showed a decrease in 
fluorescence, probably biphasic, but practically no 
initial phase of competition as was observed with 
agonists (fig.1). In contrast, the more hydrophilic 
local anesthetic procaine showed a phase of com- 
petition (fluorescence increase) followed by a phase 
of state transition (fluorescence decrease). In addi- 
tion, procaine was much less powerful than dibu- 
Caine in inducing the state transition. 
4. CONCLUSIONS 
Our studies extend previous findings of an 
agonist-induced transition to a state of high 
affinity [11,16,17,21-231 and of conformational 
changes in the course of ligand binding [24,25] of 
the acetylcholine receptor. They establish the re- 
producibility and significance of an effect first ob- 
served by authors in [ 161 but not studied in further 
detail by them. Employing equilibrium binding 
and kinetic studies and several representative 
ligands of the receptor we can now draw the fol- 
lowing conclusions on the observed state transition 
of the acetylcholine receptor: 
0) 
(ii) 
(iii) 
The transition is observed with membrane- 
bound but not with purified receptor [6,7] 
and, thus, requires the presence of membrane 
components or the existence of a particular 
conformation of the receptor lost during solu- 
bilization and purification; 
The transition is induced only by agonists and 
local anesthetics, i.e., by ligands known to 
affect the properties of the receptor-integrated 
channel but not by antagonists; 
The time course of the transition conforms to 
the slow process of desensitization. 
Our studies do not suffice to establish the molec- 
ular basis of the isomerization process. In the case 
of agonists it is tempting to assume that the transi- 
tion is caused by the same mechanism underlying 
the positive cooperativity of agonist binding sites 
[8]. However, since local anesthetics are assumed 
to bind to separate sites at the receptor-channel 
complex, the latter ligands would then have to in- 
232 
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duce the transition from a different site and, thus, 
by a different molecular mechanism. Another pos- 
sibility not excluded by the present study is to 
assume a common regulatory site structurally 
distinct from the agonist binding sites for both 
cholinergic agonists and local anesthetics at the 
receptor-channel complex. 
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